Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.54 |
| ▸ | GGT1 | P19440 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CFD | P00746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27908567 | 0.83 | LMNA (0.59) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL16719158 | 0.79 | CFD (0.73) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL4613548 | 0.78 | KDM4E (0.81) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL8437912 | 0.77 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL5603081 | 0.77 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL8820224 | 0.77 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL1317441 | 0.77 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10CYP2C19 | |
| SCHEMBL22587845 | 0.77 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDCYP2C19TSHR | |
| SCHEMBL7850984 | 0.76 | KMT2A (0.63) | KDM4EALDH1A1HPGDCYP2C19USP2 | |
| SCHEMBL1618302 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1HPGDCYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | NOGRA PHARMA LIMITED (IE) | 2020-07-30 | — | — | US | disclosed |
| US-10473669-B2 | Methods for treating inflammatory bowel disease | NOGRA PHARMA LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION | 2019-04-18 | — | — | US | disclosed |
| EP-3355896-A2 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | Nogra Pharma Limited (IE) | 2018-08-08 | — | — | EP | disclosed |
| US-20180180630-A1 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | NOGRA PHARMA LIMITED (IE) | 2018-06-28 | — | — | US | disclosed |
| EP-3237018-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | Celgene Alpine Investment Company II, LLC (BM) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017055611-A9 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | NOGRA PHARMA LIMITED (IE) | 2017-07-27 | — | — | WO | disclosed |
| EP-3140658-A2 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Nogra Pharma Limited (IE) | 2017-03-15 | — | — | EP | disclosed |
| WO-2016105516-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | CELGENE CORPORATION (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015169966-A2 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | NOGRA PHARMA LIMITED (IE) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112608-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES | SMAD3, SMAD2, SOST | KDM4E 2900/4885ALDH1A1 4038/4885HPGD 4638/4885 |
| US-20200237801-A1 | METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION | SMAD3, SMAD2, SOST | KDM4E 3645/4885ALDH1A1 3968/4885HPGD 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.